These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1115 related articles for article (PubMed ID: 2475950)
1. Effectiveness and toxicity of "BELD" polychemotherapy in advanced malignant melanoma. Cartei G; Ceschia T; Marsilio P; Clocchiatti L; Fasola G; Morandini G; Galletti D; Sibau A Tumori; 1989 Jun; 75(3):229-32. PubMed ID: 2475950 [TBL] [Abstract][Full Text] [Related]
2. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Young DW; Lever RS; English JS; MacKie RM Cancer; 1985 May; 55(9):1879-81. PubMed ID: 2579722 [TBL] [Abstract][Full Text] [Related]
3. Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. Stables GI; Doherty VR; MacKie RM Br J Dermatol; 1992 Nov; 127(5):505-8. PubMed ID: 1281672 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. Carmo-Pereira J; Costa FO; Henriques E Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1435-9. PubMed ID: 3595669 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group. Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736 [TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Pectasides D; Yianniotis H; Alevizakos N; Bafaloukos D; Barbounis V; Varthalitis J; Dimitriadis M; Athanassiou A Br J Cancer; 1989 Oct; 60(4):627-9. PubMed ID: 2803936 [TBL] [Abstract][Full Text] [Related]
7. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616 [TBL] [Abstract][Full Text] [Related]
8. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. Pyrhönen S; Hahka-Kemppinen M; Muhonen T J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673 [TBL] [Abstract][Full Text] [Related]
9. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Jungnelius U; Ringborg U; Aamdal S; Mattsson J; Stierner U; Ingvar C; Malmström P; Andersson R; Karlsson M; Willman K; Wist E; Bjelkengren G; Westberg R Eur J Cancer; 1998 Aug; 34(9):1368-74. PubMed ID: 9849419 [TBL] [Abstract][Full Text] [Related]
10. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]. Kirchner HH; Atzpodien J; Poliwoda H Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119 [TBL] [Abstract][Full Text] [Related]
11. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917 [TBL] [Abstract][Full Text] [Related]
12. Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. Bajetta E; Buzzoni R; Viviani S; Vaglini M; Nava M; Bonadonna G Am J Clin Oncol; 1985 Oct; 8(5):401-5. PubMed ID: 3904398 [TBL] [Abstract][Full Text] [Related]
13. [Results of a randomized polychemotherapy study in malignant melanoma]. Fiedler H; Hetschko I; Wohlrab W; Wozniak KD; Lübbe D; Taube KM Hautarzt; 1990 Jul; 41(7):369-74. PubMed ID: 1698185 [TBL] [Abstract][Full Text] [Related]
14. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623 [TBL] [Abstract][Full Text] [Related]
15. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial. Ringborg U; Jungnelius U; Hansson J; Strander H Am J Clin Oncol; 1990 Jun; 13(3):214-7. PubMed ID: 2346126 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma. Mulder NH; Sleijfer DT; Smit JM; De Vries EG; Willemse PH; Koops HS Eur J Cancer Clin Oncol; 1986 Jul; 22(7):879-81. PubMed ID: 2429842 [TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with dacarbazine and lomustine in disseminated malignant melanoma. Joensuu H; Asola R; Minn H Acta Radiol Oncol; 1986; 25(3):177-9. PubMed ID: 3020881 [TBL] [Abstract][Full Text] [Related]
18. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Seigler HF; Lucas VS; Pickett NJ; Huang AT Cancer; 1980 Dec; 46(11):2346-8. PubMed ID: 6159960 [TBL] [Abstract][Full Text] [Related]
19. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. Mulder NH; Sleijfer DT; de Vries EG; Schraffordt Koops H; Samson MJ; Willemse PH J Cancer Res Clin Oncol; 1989; 115(1):93-5. PubMed ID: 2466036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]